Apollomics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 13

Employees

  • Stock Symbol
  • APLM

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $5.45
  • (As of Friday Closing)

Apollomics General Information

Description

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Contact Information

Formerly Known As
CBT Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 989 East Hillsdale Boulevard
  • Suite 220
  • Foster City, CA 94404
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 989 East Hillsdale Boulevard
  • Suite 220
  • Foster City, CA 94404
  • United States
+1 (650)

Apollomics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apollomics Stock Performance

As of 11-Jul-2025, Apollomics’s stock price is $5.45. Its current market cap is $6.29M with 1.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.45 $5.70 $4.47 - $35.98 $6.29M 1.1M 20.2K -$52.80

Apollomics Financials Summary

As of 31-Dec-2024, Apollomics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV (10,455) (10,455) 34,412
Revenue 0 0 0 0
EBITDA (53,539) (53,539) (172,525) (240,373)
Net Income (53,858) (53,858) (172,601) (240,811)
Total Assets 13,098 13,098 55,387 76,475
Total Debt 966 966 4,661 991
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Apollomics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Apollomics‘s full profile, request access.

Request a free trial

Apollomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology thera
Drug Discovery
Foster City, CA
13 As of 2024

San Diego, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Apollomics Competitors (44)

One of Apollomics’s 44 competitors is AnaptysBio, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnaptysBio Formerly VC-backed San Diego, CA
Mersana Therapeutics Formerly VC-backed Cambridge, MA
AnTolRx Formerly VC-backed Cambridge, MA
CalciMedica Formerly VC-backed La Jolla, CA
Altimmune Corporate Backed or Acquired Gaithersburg, MD
You’re viewing 5 of 44 competitors. Get the full list »

Apollomics Patents

Apollomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240218453-A1 Diagnostic and treatment of cancer using c-met inhibitor Pending 21-Apr-2021
EP-4162032-A2 Enzymes and regulatory proteins in tryptamine metabolism Inactive 06-Jun-2020
US-20230338294-A1 Novel pharmaceutical formulation for c-met inhibitor Pending 26-Apr-2020
US-20200405719-A1 Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint Inactive 17-Feb-2018
US-11111300-B2 Anti pd-l1 antibodies Active 05-Aug-2014 C07K16/2827
To view Apollomics’s complete patent history, request access »

Apollomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apollomics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Apollomics‘s full profile, request access.

Request a free trial

Apollomics Acquisitions (1)

Apollomics’s most recent deal was a Merger/Acquisition with Maxpro Capital Acquisition. The deal was made on 29-Mar-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Maxpro Capital Acquisition 29-Mar-2023 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Apollomics’s complete acquisitions history, request access »

Apollomics FAQs

  • When was Apollomics founded?

    Apollomics was founded in 2015.

  • Where is Apollomics headquartered?

    Apollomics is headquartered in Foster City, CA.

  • What is the size of Apollomics?

    Apollomics has 13 total employees.

  • What industry is Apollomics in?

    Apollomics’s primary industry is Drug Discovery.

  • Is Apollomics a private or public company?

    Apollomics is a Public company.

  • What is Apollomics’s stock symbol?

    The ticker symbol for Apollomics is APLM.

  • What is the current stock price of Apollomics?

    As of 11-Jul-2025 the stock price of Apollomics is $5.45.

  • What is the current market cap of Apollomics?

    The current market capitalization of Apollomics is $6.29M.

  • Who are Apollomics’s competitors?

    AnaptysBio, Mersana Therapeutics, AnTolRx, CalciMedica, and Altimmune are some of the 44 competitors of Apollomics.

  • What is Apollomics’s annual earnings per share (EPS)?

    Apollomics’s EPS for 12 months was -$52.80.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »